Logo image of TELO.CA

TELO GENOMICS CORP (TELO.CA) Stock Fundamental Analysis

Canada - TSX-V:TELO - CA87975M2085 - Common Stock

0.07 CAD
0 (-6.67%)
Last: 9/12/2025, 7:00:00 PM
Fundamental Rating

2

TELO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 24 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for TELO as it has an excellent financial health rating, but there are worries on the profitability. TELO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TELO has reported negative net income.
TELO had a negative operating cash flow in the past year.
TELO had negative earnings in each of the past 5 years.
TELO had a negative operating cash flow in each of the past 5 years.
TELO.CA Yearly Net Income VS EBIT VS OCF VS FCFTELO.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

TELO has a Return On Assets (-186.84%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -232.51%, TELO is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
ROA -186.84%
ROE -232.51%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TELO.CA Yearly ROA, ROE, ROICTELO.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TELO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TELO.CA Yearly Profit, Operating, Gross MarginsTELO.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

There is no outstanding debt for TELO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TELO.CA Yearly Shares OutstandingTELO.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
TELO.CA Yearly Total Debt VS Total AssetsTELO.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M

2.2 Solvency

Based on the Altman-Z score of -18.72, we must say that TELO is in the distress zone and has some risk of bankruptcy.
TELO has a Altman-Z score (-18.72) which is in line with its industry peers.
There is no outstanding debt for TELO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.72
ROIC/WACCN/A
WACCN/A
TELO.CA Yearly LT Debt VS Equity VS FCFTELO.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M -6M -8M

2.3 Liquidity

A Current Ratio of 4.95 indicates that TELO has no problem at all paying its short term obligations.
TELO's Current ratio of 4.95 is amongst the best of the industry. TELO outperforms 83.33% of its industry peers.
A Quick Ratio of 4.95 indicates that TELO has no problem at all paying its short term obligations.
The Quick ratio of TELO (4.95) is better than 83.33% of its industry peers.
Industry RankSector Rank
Current Ratio 4.95
Quick Ratio 4.95
TELO.CA Yearly Current Assets VS Current LiabilitesTELO.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M

More info and screens

0

3. Growth

3.1 Past

TELO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.81%, which is quite impressive.
EPS 1Y (TTM)25.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TELO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TELO.CA Price Earnings VS Forward Price EarningsTELO.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TELO.CA Per share dataTELO.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.01 -0.01 -0.02

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TELO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TELO GENOMICS CORP

TSX-V:TELO (9/12/2025, 7:00:00 PM)

0.07

0 (-6.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)06-03 2025-06-03
Earnings (Next)10-23 2025-10-23
Inst Owners2.06%
Inst Owner ChangeN/A
Ins Owners4.05%
Ins Owner ChangeN/A
Market Cap7.03M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.26
P/tB 6.35
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -186.84%
ROE -232.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.45%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.95
Quick Ratio 4.95
Altman-Z -18.72
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)88.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.18%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.29%
OCF growth 3YN/A
OCF growth 5YN/A